Physician profile
Kelsey P Martin
NPI 1619478559
$41,835.96
in general payments reported to CMS, 2019-2025
60 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $730 · 2023: $6,894 · 2024: $17K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $9,436 · Food and Beverage: $8,610 · Consulting Fee: $880 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,745.00 |
| Travel and Lodging | $9,435.83 |
| Food and Beverage | $8,610.25 |
| Consulting Fee | $880.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33,281.71 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $1,095.51 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Stemline Therapeutics INC. | $932.41 | 2023-2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $862.69 | 2021-2025 | Libtayo, Dupixent |
| Daiichi Sankyo INC. | $719.43 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $534.93 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $399.69 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $301.68 | 2022-2025 | |
| Janssen Biotech, INC. | $266.60 | 2022-2025 | Rybrevant, Akeega, Balversa |
| E.R. Squibb & Sons, L.L.C. | $204.23 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $188.07 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.46 | 2022-2024 | |
| Tersera Therapeutics LLC | $163.12 | 2023-2025 | Zoladex, Quzyttir, Xermelo |
| Lilly USA, LLC | $150.90 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Exelixis INC. | $130.56 | 2023-2025 | Cabometyx |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $121.70 | 2023-2024 | Fotivda |
| Genzyme Corporation | $121.17 | 2022-2025 | |
| Genentech USA, INC. | $114.43 | 2023-2025 | Phesgo, Tecentriq, Itovebi |
| Celgene Corporation | $114.13 | 2022-2025 | Reblozyl, Abecma, Breyanzi |
| Emd Serono, INC. | $100.14 | 2023-2025 | Tepmetko, Bavencio |
| Array Biopharma INC | $99.37 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Servier Pharmaceuticals LLC | $98.49 | 2023-2025 | |
| Astellas Pharma US INC | $95.88 | 2023-2025 | Padcev, Xtandi |
| Seagen INC. | $91.79 | 2023 | Tukysa, Padcev |
| Incyte Corporation | $91.03 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| G1 Therapeutics, INC. | $90.96 | 2023 | Cosela |
| Jazz Pharmaceuticals INC. | $79.29 | 2022-2024 | |
| Mirati Therapeutics, INC. | $76.15 | 2023-2024 | Krazati |
| Springworks Therapeutics, INC. | $73.18 | 2025 | Gomekli, Ogsiveo |
| Genmab U.S., INC. | $70.99 | 2024-2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $66.84 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Organon LLC | $62.53 | 2023 | Ontruzant |
| Abbvie INC. | $51.07 | 2022-2025 | |
| Puma Biotechnology, INC. | $51.03 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $50.24 | 2024 | Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $48.78 | 2023 | Ninlaro |
| Beigene USA, INC. | $48.74 | 2022-2024 | Brukinsa |
| Tempus Ai, INC | $47.05 | 2024-2025 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $45.32 | 2023 | Pylarify |
| Amgen INC. | $43.94 | 2023 | Lumakras |
| Blueprint Medicines Corporation | $42.32 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $41.38 | 2025 | Tevimbra, Brukinsa |
| Novocure INC. | $35.11 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $34.32 | 2024-2025 | |
| Caris Mpi, INC. | $33.83 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $30.03 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $24.58 | 2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $22.52 | 2024 | Ultomiris |
| Verity Pharmaceuticals INC. | $21.32 | 2024 | Trelstar |
| Iovance Biotherapeutics, INC. | $21.00 | 2025 | Amtagvi |
| Celltrion USA INC. | $19.57 | 2025 | Vegzelma |
| Cti Biopharma Corp. | $18.94 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $18.92 | 2024 | |
| Glaxosmithkline, LLC. | $18.68 | 2025 | Ojjaara |
| Pharmaessentia USA Corporation | $18.20 | 2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.12 | 2024 | Gilotrif |
| Spectrum Pharmaceuticals INC. | $16.81 | 2023 | Rolvedon |
| Kyowa Kirin, INC. | $16.36 | 2024 | Poteligeo |
| Sobi, INC | $16.16 | 2024 | |
| Pharmacosmos Therapeutics INC. | $13.56 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.